Résumé
Awareness, diagnosis and treatment of COPD, compared to other major causes of death, remains far too low. This article describes the protocol objectives, design and the approaches taken in the Canadian Chronic Obstructive Lung Disease (CanCOLD) study, an epidemiological and integrated research. The CanCOLD study aims at better understanding heterogeneity of COPD presentation and disease progression. We hypothesize that individuals with unfavourable COPD "phenotypes" and subjects at-risk (ever smokers) with unhealthy lifestyle habits, environmental/work exposure, or co-morbidities will have increased risk of lung function decline independent of their cumulative exposure to cigarette smoke. The study is a prospective multi-center cohort study (9 sites in 6 provinces) built on the Canadian COPD prevalence study "COLD." The study plan is to include 1800 subjects at least 40 years old who were sampled from the general population and who were found to fall within 4 groups: 1) COPD moderate-severe (GOLD 2-4); 2) COPD mild (GOLD 1); 3) subjects at-risk (ever smoker); and, 4) subjects never-smoker free of airflow obstruction. Data collection is based on using strictly standardized methods involving questionnaires, pulmonary function and cardiorespiratory exercise tests, CT scans, and blood sampling. CanCOLD is a unique study that will address challenging and important research questions on COPD disease evolution and disease management and will help to define the natural history of COPD disease evolution in individuals at-risk for COPD and in those with COPD who have mild disease.
| Langue d'origine | English |
|---|---|
| Pages (de-à) | 125-132 |
| Nombre de pages | 8 |
| Journal | COPD: Journal of Chronic Obstructive Pulmonary Disease |
| Volume | 11 |
| Numéro de publication | 2 |
| DOI | |
| Statut de publication | Published - avr. 2014 |
Note bibliographique
Funding Information:The successful completion of this study will only be possible through the commitment of the participants and the dedication of the study personnel from the national coordination and each participating site. The authors wish to thank the Laboratoire de Télématique Biomédi-cale du Réseau en Santé Respiratoire du Fonds de la Recherche en Santé du Québec (FRSQ).
Funding Information:
The Canadian Cohort Obstructive Lung Disease (CanCOLD) is funded by the Canadian Institute of Heath Research (CIHR/Rx&D Collaborative Research Program Operating Grants-93326); industry partners Astra Zeneca Canada Ltd., Boehringer-Ingelheim Canada Ltd., GlaxoSmithKline Canada Ltd, Merck, Novartis Pharma Canada Inc., Nycomed Canada Inc., Pfizer Canada Ltd.; the Respiratory Health Network of the FRSQ and the Research Institute of the McGill University Health Centre.
Funding Information:
J. Bourbeau reports receiving research funding via the Research Institute of the McGill University Health Centre, from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer and Theratechnologies; and has served on speakers, consultation panels and/or advisory boards for the above listed pharmaceutical companies. W.C. Tan has no potential conflict of interest relevant to this article. A. Benedetti has no potential conflict of interest relevant to this article. SD Aaron has no potential conflict of interest relevant to this article. K.R. Chapman has received compensation for consulting with AstraZeneca, Boehringer-Ingelheim, CSL Behring, GlaxoSmithKline, Merck Frosst, Novartis, Nycomed, Pfizer, Roche, Shering Plough and Talecris; he has undertake research funded by AstraZeneca, Boehringer-Ingelheim, CSL Behring, Forest Labs, GlaxoS-mithKline, Novartis, Parangenix, Roche and Talecris; and has participated in continuing medical education activities sponsored in whole or in part by AstraZeneca, Boehringer-Ingelheim, CSL Behring, Grifols, Merck Frosst, Novartis, Nycomed, Pfizer, and Telacris. H. Cox-son has served on the steering committee for ECLIPSE project for GSK. In addition, he was the co-investigator on two multicentre studies sponsored by GSK and has received travel expenses to attend meeting related to the project. He had three contract service agreements with GSK to quantify the CT scans in subjects with COPD and has a service agreement with Spiration Inc. to measure changes in lung volume in subject with severe emphysema. He has received a fee for speaking at a conference and related travel expenses from Astra-Zeneca. He was the recipient of a GSK Clinical Scientist Award (2010-2011). R. Cowie has no potential conflict of interest relevant to this article. J.M. Fitzgerald has no potential conflict of interest relevant to this article. R. Goldstein has no potential conflict of interest relevant to this article. P. Hernandez has participated in industry-sponsored clinical trials and continuing education events and medical advisory boards for the following companies: AstraZeneca, Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKline, Novartis, Nycomed, Pfizer, CSL Behring, Actelion, Merck Frosst. J. Leipsic has no potential conflict of interest relevant to this article. F. Maltais has no potential conflict of interest relevant to this article. D. Marciniuk has no potential conflict of interest relevant to this article. D. O’Donnell has no potential conflict of interest relevant to this article. D.D. Sin has no potential conflict of interest relevant to this article. The authors are entirely responsible for the content and writing of this paper.
ASJC Scopus Subject Areas
- Pulmonary and Respiratory Medicine